Meta- analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to reduce both the risk of severe asthma exacerbation and healthcare use .
Children and people with frequent severe asthma exacerbations were under-represented ; additional primary trials are needed to establish whether vitamin D can reduce the risk of severe asthma exacerbation in these groups
BACKGROUND Several clinical trials of vitamin D to prevent  asthma exacerbation  and improve  asthma control  have been conducted in children and adults , but a meta- analysis restricted to double-blind , r and omised , placebo-controlled trials of this intervention is lacking .
OBJECTIVES To evaluate the efficacy of administration of vitamin D and its hydroxylated metabolites in reducing the risk of severe asthma exacerbations ( defined as those requiring treatment with systemic corticosteroids ) and improving asthma symptom control .
Vitamin D and omega-3 polyunsaturated fatty acid supplementation in athletes with exercise-induced bronchoconstriction: a pilot study
Objective : The aim of this pilot study was to determine the combined effect of vitamin D and omega-3 polyunsaturated fatty acid ( PUFA ) supplementation on airway function and inflammation in recreational athletes with exercise-induced bronchoconstriction ( EIB ) . Methods : Ten recreational athletes with EIB participated in a single-blind , placebo-controlled trial over six consecutive weeks . All subjects attended the laboratory on three occasions . Each visit was separated by a period of 3 weeks : visit 1 ( usual diet ) , visit 2 ( placebo ) and visit 3 ( SMARTFISH ® NutriFriend 2000 ; 30 µg vitamin D3–3000 mg eicosapentaenoic acid , 3000 mg docosahexaenoic acid ) consumed once daily for a period of 3 weeks . Venous blood was collected at the beginning of each trial to determine  vitamin  D status . Spirometry was performed pre- and post-eucapnic voluntary hyperpnoea ( EVH ) . Results : The Maximum fall in FEV1 ( ΔFEV1max ) post-EVH was not different between visits ( usual diet : −15.9 ± 3.6 % , placebo : −16.1 ± 6.1 % , vitamin D + omega-3 PUFA : −17.8 ± 7.2 % ) . Serum vitamin  D remained unchanged between visits . Conclusion : Vitamin D and omega-3 PUFA supplementation does not attenuate the reduction in lung function post-EVH . This finding should be viewed as preliminary until the results of r and omised controlled trials are made available
Meta- analysis of a modest number of trials in people with predominantly mild to moderate asthma suggests that vitamin D is likely to reduce both the risk of severe asthma exacerbation and healthcare use .
Children and people with frequent severe asthma exacerbations were under-represented ; additional primary trials are needed to establish whether vitamin D can reduce the risk of severe asthma exacerbation in these groups
BACKGROUND Several clinical trials of vitamin D to prevent  asthma exacerbation  and improve  asthma control  have been conducted in children and adults , but a meta- analysis restricted to double-blind , r and omised , placebo-controlled trials of this intervention is lacking .
OBJECTIVES To evaluate the efficacy of administration of vitamin D and its hydroxylated metabolites in reducing the risk of severe asthma exacerbations ( defined as those requiring treatment with systemic corticosteroids ) and improving asthma symptom control .